Connect with us
European Gaming Congress 2024

Artificial Intelligence

Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain

Published

on

<!– Name:DistributionId Value:8736375 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:d450ecdf-f8de-44dd-ae95-b7892935e4aa –>

New York, USA, Jan. 30, 2023 (GLOBE NEWSWIRE) — Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain

The prevalence of thrombocytopenia has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Thrombocytopenia and the growing research and development activities to develop novel therapies to treat Thrombocytopenia to drive the market. The companies developing the potential therapies in the last stage of development include argenx, HUTCHMED, Takeda, and several others.

DelveInsight’s Thrombocytopenia Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline thrombocytopenia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the thrombocytopenia pipeline domain.

Key Takeaways from the Thrombocytopenia Pipeline Report

Advertisement
Stake.com
  • DelveInsight’s thrombocytopenia pipeline report depicts a robust space with 27+ active players working to develop 30+ pipeline therapies for thrombocytopenia treatment. 
  • Key thrombocytopenia companies such as Takeda, argenx, Keros Therapeutics, Sanofi, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, Qilu Pharmaceutical, Jiangsu HengRui Medicine Co., Ltd., InnoCare Pharma, eXIthera Pharmaceuticals, Harbour BioMed (Guangzhou) Co. Ltd., CTI BioPharma, AO GENERIUM,  Chugai Pharmaceutical, Takeda, PhytoHealth Corporation, Inmunova S.A., Biotest Pharmaceuticals, COUR Pharmaceuticals, HanAll Biopharma, and others are evaluating new drugs for thrombocytopenia to improve the treatment landscape.
  • Promising thrombocytopenia pipeline therapies in various stages of development include Mezagitamab, Efgartigimod alfa, KER 050, Rilzabrutinib, VLX 1005, Iptacopan, PF 06755347, Sovleplenib, PF 06835375, Cevidoplenib, Rozanolixizumab, QL0911, Hetrombopag, Ianalumab,  Orelabrutinib,  EP-7041, HBM9161, PACIFICA, GNR-069,  Crovalimab, TAK 755, PHN013, INM004,  BT-595, CNP-105,  HL161, and others.
  • In January 2023, Takeda announced that the totality of evidence from a pre-planned interim analysis of a pivotal Phase III study supports the efficacy and safety of TAK-755 as enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP).The interim results showed that TAK-755 reduced the incidence of thrombocytopenia events by 60% (95% Confidence Interval, 30%-70%), an important marker of disease activity in cTTP, as compared to SoC. The proportion of subjects experiencing adverse events determined to be related to the treatment was substantially lower among subjects during treatment with TAK-755 (8.9%) compared to that while receiving SoC therapy (47.7%).
  • In January 2023, HUTCHMED (China) Limited (“HUTCHMED”) announced that it had completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) in China. The last patient was enrolled on December 31, 2022.The ESLIM-01 study, initiated in October 2021, is a randomized, double-blinded, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of sovleplenib in treating adult patients with ITP. The primary endpoint of the study is the durable response rate. Secondary and exploratory endpoints include overall response rate (ORR), the incidence of treatment-emergent adverse events, and patient quality of life improvement. A total of 188 patients were enrolled.
  • In April 2022, Biotest AG announced that the marketing authorisation application for the Biotest development product IgG Next Generation in the so-called decentralized procedure (DCP) was submitted in Germany and Austria by 31 March 2022. IgG Next Generation is the first product to be produced in Biotest’s new manufacturing facility Biotest Next Level (BNL).The marketing authorization application covers the biochemical-pharmaceutical-technical part, as well as the preclinical and clinical studies in the indications Primary Immunodeficiency Diseases (PID) and chronic Primary Immune Thrombocytopenia (ITP).
  • In April 2022, Positive results from the Phase I/II dose-finding study evaluating the safety, pharmacokinetics, and clinical activity of rilzabrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrated treatment with rilzabrutinib led to a rapid and durable increase in platelet count and supported an acceptable safety profile. Sanofi is investigating the safety and efficacy of twice daily rilzabrutinib (400 mg) for adults and adolescents with chronic ITP in the ongoing Phase 3 clinical study LUNA 3, initiated in April 2021.
  • In May 2022, argenx SE announced positive data from the Phase III ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary ITP. ADVANCE met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo. ADVANCE is the first Phase 3 clinical trial of a neonatal Fc receptor (FcRn) blocker in ITP.
  • In January 2022HUTCHMED (China) Limited announced that the Center for Drug Evaluation of China’s National Medical Products Admin­istration (“NMPA”) has granted Break­through Therapy Designation (“BTD”) to HMPL-523, a novel, investiga­tional spleen tyrosine kinase (“Syk”) inhibitor, for the treat­ment of chronic adult primary immune thrombo­cytopenia (“ITP”) patients who have received at least one prior therapy.

Request a sample and discover the recent advances in thrombocytopenia treatment drugs @ Thrombocytopenia Pipeline Report

The thrombocytopenia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage thrombocytopenia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the thrombocytopenia clinical trial landscape.

Thrombocytopenia Overview

Thrombocytopenia is the medical term for a platelet count that is less than 150000/microliter (for adults), the lower limit of normal. The hazards of thrombocytopenia range from no danger at all to bleeding risks and thrombosis. Platelets are blood cells that aid in blood clotting and wound healing. Uncertainty exists regarding the relationship between bleeding risk and thrombocytopenia severity. Platelet counts below 10,000/microliter can cause spontaneous bleeding, and numbers below 50,000/microL can cause surgical bleeding. Heparin-induced thrombocytopenia (HIT), antiphospholipid antibody syndrome (APS), disseminated intravascular coagulation (DIC), thrombotic microangiopathy (TMA), and paroxysmal nocturnal hemoglobinuria are a few situations where thrombocytopenia is linked to a risk of thrombosis (PNH). According to a prospective study, patients with mild thrombocytopenia (100000 to 150000/microliter) have a 10-year likelihood of acquiring autoimmune diseases, according to a prospective study.

Find out more about thrombocytopenia treatment drugs @ Drugs for Thrombocytopenia Treatment 

A snapshot of the Thrombocytopenia Pipeline Drugs mentioned in the report:

Advertisement
Stake.com
Drugs Company Phase  MoA RoA
Efgartigimod alfa  argenx Phase III Neonatal Fc receptor antagonists Intravenous
Sovleplenib HUTCHMED Phase III Syk kinase inhibitors Oral
Cevidoplenib Genosco Phase II Syk kinase inhibitors Oral
Mezagitamab Takeda Phase II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Subcutaneous
KER 050 Keros Therapeutics Phase II Erythropoiesis stimulants; Transforming growth factor beta inhibitors Subcutaneous
VLX 1005 Veralox Therapeutics Phase I 12-lipoxygenase inhibitors; Platelet aggregation inhibitors Intravenous
PF 06755347 Pfizer Phase I Immunomodulators Intravenous

Learn more about the emerging thrombocytopenia pipeline therapies @ Thrombocytopenia Clinical Trials

Thrombocytopenia Therapeutics Assessment

The thrombocytopenia pipeline report proffers an integral view of thrombocytopenia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Thrombocytopenia Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous
  • Therapeutics Assessment By Molecule Type: Small molecule, Cell Therapy, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Neonatal Fc receptor antagonists, Syk kinase inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Erythropoiesis stimulants, Transforming growth factor beta inhibitors, 12-lipoxygenase inhibitors, Platelet aggregation inhibitors, Immunomodulators
  • Key Thrombocytopenia Companies: Takeda, argenx, Keros Therapeutics, Sanofi, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, Qilu Pharmaceutical, Jiangsu HengRui Medicine Co., Ltd., InnoCare Pharma, eXIthera Pharmaceuticals, Harbour BioMed (Guangzhou) Co. Ltd., CTI BioPharma, AO GENERIUM,  Chugai Pharmaceutical, Takeda, PhytoHealth Corporation, Inmunova S.A., Biotest Pharmaceuticals, COUR Pharmaceuticals, HanAll Biopharma and others.
  • Key Thrombocytopenia Pipeline Therapies: Mezagitamab, Efgartigimod alfa, KER 050, Rilzabrutinib, VLX 1005, Iptacopan, PF 06755347, Sovleplenib, PF 06835375, Cevidoplenib, Rozanolixizumab, QL0911, Hetrombopag, Ianalumab,  Orelabrutinib,  EP-7041, HBM9161, PACIFICA, GNR-069,  Crovalimab, TAK 755, PHN013, INM004,  BT-595, CNP-105,  HL161, and others.

Dive deep into rich insights for new drugs for thrombocytopenia treatment; visit @ Thrombocytopenia Drugs

Table of Contents

Advertisement
Stake.com
1. Thrombocytopenia Pipeline Report Introduction
2. Thrombocytopenia Pipeline Report Executive Summary
3. Thrombocytopenia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Thrombocytopenia Clinical Trial Therapeutics
6. Thrombocytopenia Pipeline: Late Stage Products (Pre-registration)
7. Thrombocytopenia Pipeline: Late Stage Products (Phase III)
7.1. Efgartigimod alfa: argenx
8. Thrombocytopenia Pipeline: Mid Stage Products (Phase II)
8.1. Cevidoplenib: Genosco
9. Thrombocytopenia Pipeline: Early Stage Products (Phase I)
9.1. VLX 1005: Veralox Therapeutics
10. Thrombocytopenia Pipeline Therapeutics Assessment
11. Inactive Products in the Thrombocytopenia Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Thrombocytopenia Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the thrombocytopenia pipeline therapeutics, reach out @ Thrombocytopenia Medications

Related Reports

Thrombocytopenia Market

Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thrombocytopenia companies, including Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, among others.

Immune Thrombocytopenia Market

Advertisement
Stake.com

Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies, including Takeda, Biotest, GC Pharma,  UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, among others.

Immune Thrombocytopenia Pipeline

Immune Thrombocytopenia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune thrombocytopenia companies, including Takeda, Biotest, GC Pharma,  UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, among others.

Immune Thrombocytopenia Epidemiology Forecast

Immune Thrombocytopenia Epidemiology Forecast – 2033 report delivers an in-depth understanding of the disease, historical and forecasted immune thrombocytopenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Advertisement
Stake.com

Helicobacter pylori Infection Market

Helicobacter pylori Infection Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Helicobacter pylori infection companies, including Phathom Pharmaceuticals, Redhill Biopharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, among others.

Helicobacter pylori Infection Pipeline

Helicobacter pylori Infection Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Helicobacter pylori infection companies, including Phathom Pharmaceuticals, Redhill Biopharma, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, among others.

Other Trending Reports

Advertisement
Stake.com

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

Advertisement
Stake.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Industrial Robotics Market is Slated to Transcend USD 44.87 Billion Valuation by 2031-end, Automation of Industrial Operations to Promote Market Expansion | SkyQuest Technology

Published

on

industrial-robotics-market-is-slated-to-transcend-usd-44.87-billion-valuation-by-2031-end,-automation-of-industrial-operations-to-promote-market-expansion-|-skyquest-technology

WESTFORD, Mass., July 12, 2024 /PRNewswire/ — According to SkyQuest, the global Industrial Robotics Market size was valued at USD 14.7 Billion in 2022 and is poised to grow from USD 16.6 Billion in 2023 to USD 44.87 Billion by 2031, at a CAGR of 13.2% during the forecast period (2024-2031).

Increasing use of advanced digital technologies in industries to improve the productivity of industrial operations is slated to bolster the demand for industrial robotics. The development of novel industrial robots and the rising acceptance of the same in different industry verticals will also favor industrial robotics market development in the future. The global industrial robotics market is segmented into type, payload, component, application, end use, and region.
Download a detailed overview:https://www.skyquestt.com/sample-request/industrial-robotics-market
Industrial Robotics Market Overview:
Report Coverage
Details
Market Revenue in 2023
$ 16.6 billion
Estimated Value by 2031
$ 44.87 billion
Growth Rate
Poised to grow at a CAGR of 13.2%
Forecast Period
2024–2031
Forecast Units
Value (USD Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Type, Payload, Component, Application and End Use,
Geographies Covered
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
Rising adoption of automation in industrial applications
Key Market Drivers
Advancements in robotics technologies and increasing acceptance of robots in industrial settings
Segments covered in Industrial Robotics Market are as follows:
TypeTraditional Robots (Articulated Robots, Cartesian Robots, SCARA Robots, Parallel Robots, Cylindrical Robots, Others), and Collaborative RobotsPayloadUp to 16.00 kg, 16.01–60.00 kg, 60.01–225.00 kg, and More than 225.00 kgComponentRobot Arm, Robot Accessories, Additional Robotic Hardware, System Engineering, and Software & ProgrammingApplicationHandlings, Assembling & Disassembling, Welding & Soldering, Clean Room, Dispensing, Processing, and OthersEnd-UseAutomotive, Electrical & Electronics, Metals & Machinery, Plastics, Rubbers, & Chemicals, Food & Beverages, Precision Engineering & Optics, Pharmaceuticals & Cosmetics, Oil & Gas, and OthersRequest Free Customization of this report:https://www.skyquestt.com/speak-with-analyst/industrial-robotics-market
Efficient Material Handling Demands are Estimated to Govern the Global Sales of Industrial Robotics
Increasing demand for better productivity and operational efficiency in industries has resulted in the adoption of better material handling technologies. Industrial robots are highly efficient and adaptable to multiple handling operations, which is why they are being extensively used for this application. Any company investing in this segment is projected to get lucrative returns on their investments in the long run.
Demand for Better Human-Machine Interactions to Drive Use of Collaborative Industrial Robots
Collaborative robots have been gaining massive popularity around the world owing to their better human-machine interaction capabilities. Industrial robotics providers should focus on utilizing artificial intelligence and machine learning technologies to maximize the efficiency of their offerings. Growing emphasis on worker safety is also a key factor that is projected to bolster the demand for collaborative industrial robotics across the forecast period.
View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/industrial-robotics-market
Industrial Robots are Highly Popular Among Electronics and Electrical Industry for Multiple Operations
Rapidly surging demand for electronics and electrical components around the world owing to the adoption of digital technologies is driving the demand for industrial robotics. Almost all aspects of electronics manufacturing are being automated, which is why industrial robotics is projected to shine bright in the electronics and electrical industry.
Industries dealing with plastics, chemicals, and rubber are also projected to witness a robust hike in demand for industrial robotics. The automotive industry is also a key end user of industrial robotics and will be a key segment that most companies target in the future.  The use of industrial robots to perform hazardous and dangerous tasks is projected to increase as emphasis on worker safety rises.
Increasing digital transformation of multiple industry verticals will also create a highly opportune setting for industrial robotics companies no matter what industry they choose to target. Industry 4.0 trend and growing preference for automation are also estimated to uplift the sales of industrial robotics over the coming years.
Related Report:
Robotics Market
Service Robotics Market
Delivery Robots Market
Warehouse Robotics Market
Smart Robots Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:Mr. Jagraj SinghSkyQuest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/industrial-robotics-market-is-slated-to-transcend-usd-44-87-billion-valuation-by-2031-end-automation-of-industrial-operations-to-promote-market-expansion–skyquest-technology-302195662.html

Continue Reading

Artificial Intelligence

Artificial Intelligence (AI) in Manufacturing Market Valued at USD 64.63 Billion by 2031 | SkyQuest Technology

Published

on

artificial-intelligence-(ai)-in-manufacturing-market-valued-at-usd-64.63-billion-by-2031-|-skyquest-technology

WESTFORD, Mass., July 12, 2024 /PRNewswire/ — According to SkyQuest, the global Artificial Intelligence (AI) in Manufacturing Market size was valued at USD 2.58 Billion in 2022 and is expected to grow from USD 3.20 Billion in 2023 to reach USD 64.63 Billion by 2031, at a CAGR of 45.6% during the forecast period (2024-2031).

Artificial intelligence helps boost factory productivity and efficiency in manufacturing industry and is therefore getting adopted at a rapid pace. The objective of optimizing manufacturing processes and the increasing adoption of Industry 4.0 is driving the demand for AI in manufacturing. The global market for AI in manufacturing is categorized by components, technology, applications, end-users, and regions.
Download a detailed overview:https://www.skyquestt.com/sample-request/artificial-intelligence-in-manufacturing-market
Artificial Intelligence (AI) In Manufacturing Market Overview:
Report Coverage
Details
Market Revenue in 2023
$ 3.20 Billion
Estimated Value by 2031
$ 64.63 Billion
Growth Rate
Poised to grow at a CAGR of 45.6%
Forecast Period
2024–2031
Forecast Units
Value (USD Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Component, Device Type and End User
Geographies Covered
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Report Highlights
Development of new AI in manufacturing hardware and software solutions remains prime focus of companies
Key Market Opportunities
Demand for predictive maintenance slated to create new business scope
Key Market Drivers
Computer vision and machine learning technologies to improve automation capabilities drive market growth
Segments covered in Artificial Intelligence (AI) In Manufacturing Market are as follows:
ComponentNetwork, ModuleDevice TypeWearables, Tracker, Smart Lighting, Smart Parking, Alarm & Detector, OthersEnd-UserAutomotive Industry, Infrastructure, Healthcare, Manufacturing Industry, OthersRequest Free Customization of this report:https://www.skyquestt.com/speak-with-analyst/artificial-intelligence-in-manufacturing-market
Hardware Plays a Vital Role in Adoption of Artificial Intelligence (AI) in Manufacturing
Legacy infrastructure and systems of manufacturing facilities are not compatible with advanced artificial intelligence technology thereby driving the demand for novel hardware solutions. This sub-segment covers components such as sensors, devices, processors, integrated circuits, etc. designed especially for AI in manufacturing going forward. The need for better computing power and demand for faster hardware configurations will also help this segment bolster artificial intelligence (AI) in manufacturing market growth in the future.
Software plays a crucial role in incorporating advancements of AI technology in artificial intelligence (AI) in manufacturing applications. High investments in the development of novel AI software solutions and integration of edge and cloud computing are also creating new opportunities for artificial intelligence (AI) in manufacturing providers going forward. 
Machine Learning in AI Applications for Manufacturing will help Promote Growth
Machine learning algorithms help to examine extensive datasets for providing immediate insights into manufacturing equipment and processes. Such insights help players improve their market position by optimizing operations and utilizing resources. Predictive maintenance is also largely enabled by the deployment of machine learning algorithms. High investments in machine learning technology development are also expected to alter the global artificial intelligence (AI) in manufacturing market growth trajectory vastly in the future.
Computer vision technology is projected to witness robust demand over the coming years. The growing need for automation across all kinds of manufacturing facilities is slated to create an opportune setting for artificial intelligence (AI) in manufacturing companies going forward. This technology helps machines to interpret and process visual data to make informed decisions in real time that enhance the productivity of manufacturing operations.
View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/artificial-intelligence-in-manufacturing-market
Predictive Maintenance Takes Crown When It Comes to AI Application in Manufacturing Space
Downtime is the worst nightmare of any manufacturing operation, and this is why predictive maintenance is the best companion for any manufacturing company. A growing number of manufacturing facilities deploying predictive maintenance solutions to reduce downtime allow this segment to lead global artificial intelligence (AI) in manufacturing adoption. Meanwhile, the use of AI for quality control and inspection of finished goods is also expected to rise at a robust CAGR over the coming years. Use of AI for production planning also offers lucrative opportunities for artificial intelligence (AI) in manufacturing providers in the long run.
Artificial intelligence (AI) in the manufacturing market is slated to largely benefit from the predictive maintenance sub-segment across the forecast period. Upcoming artificial intelligence (AI) in manufacturing companies should target the services sub-segment and established providers should focus on the hardware sub-segment to get the best returns in the long run. Context awareness and natural language processing technologies have a lot of untapped potential for artificial intelligence (AI) in manufacturing companies to experiment with.
Related Report:
AI Market 
Artificial Intelligence (AI) Robots Market
Artificial Intelligence (AI) in Healthcare Market
Mobile Artificial Intelligence (AI) Market
Artificial Intelligence (AI) Hardware Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:Mr. Jagraj SinghSkyQuest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-ai-in-manufacturing-market-valued-at-usd-64-63-billion-by-2031–skyquest-technology-302195681.html

Continue Reading

Artificial Intelligence

Artificial Intelligence (AI) in Cybersecurity Market to Surpass USD 114.30 Billion Valuation in 2031 on the Back of Rapidly Evolving Threat Landscape | SkyQuest Technology

Published

on

artificial-intelligence-(ai)-in-cybersecurity-market-to-surpass-usd-114.30-billion-valuation-in-2031-on-the-back-of-rapidly-evolving-threat-landscape-|-skyquest-technology

WESTFORD, Mass., July 12, 2024 /PRNewswire/ — According to SkyQuest, the global Artificial Intelligence (AI) in Cybersecurity Market size was valued at USD 18.36 Billion in 2022 and is poised to grow from USD 22.49 Billion in 2023 to USD 114.30 Billion by 2031, at a CAGR of 22.53% during the forecast period (2024-2031).

Artificial intelligence technology is being used in cybersecurity to improve the security of digital networks and solutions as the threat landscape evolves rapidly. The growing incidence of cyberattacks and the need for automation of cybersecurity are promoting the use of AI in cybersecurity. The global artificial intelligence (AI) in cybersecurity market is segmented into offering, security type, technology, application, vertical, and region.
Download a detailed overview:
https://www.skyquestt.com/sample-request/global-ai-in-cybersecurity-market
Artificial Intelligence (AI) In Cybersecurity Market Overview:
Report Coverage
Details
Market Revenue in 2023
$ 22.49 billion
Estimated Value by 2031
$ 114.30 billion
Growth Rate
Poised to grow at a CAGR of 22.53%
Forecast Period
2024–2031
Forecast Units
Value (USD Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Security Type, Technology, Application and Vertical
Geographies Covered
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Report Highlights
Emphasis on improving identity and access management to create better AI in cybersecurity solutions
Key Market Opportunities
Use of machine learning to identify potential threat patterns
Key Market Drivers
Deployment of novel AI-based cybersecurity solutions by enterprises driving market development
Segments covered in Artificial Intelligence (AI) In Cybersecurity Market are as follows:
Security TypeInfrastructure Security (Network Security, Endpoint Security, Cloud Security, and Others), Data Security, Application Security, and OthersTechnologyMachine Learning (ML), Natural Language Processing (NLP), Context-Aware ComputingApplicationIdentity & Access Management, Risk & Compliance Management, Data Loss Prevention, Unified Threat Management, Fraud Detection, and OthersVerticalBFSI, IT & Telecom, Government & Defense, Manufacturing, and OthersRequest Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/global-ai-in-cybersecurity-market
Services to Spearhead the Global Artificial Intelligence (AI) in Cybersecurity Market Growth
Artificial intelligence is a highly advanced technology, and organizations need assistance to deploy it in cybersecurity applications. From consulting to integration all kinds of services are highly vital in the global artificial intelligence (AI) in cybersecurity market growth over the coming years. Not all companies have the resources to deploy AI in cybersecurity by themselves, which is why the services sub-segment holds sway in the global market.
Rapid advancements in AI technology fuel the need for novel software solutions and updates for the same allowing the software sub-segment to boost market growth. Use of advanced machine learning algorithms and integration of other advanced technologies will also help amplify artificial intelligence (AI) in cybersecurity company’s business scope through this sub-segment. The increasing complexity of the regulatory environment and cyberattacks will always boost the demand for new software solutions.
Machine Learning is the Essence of AI in Cybersecurity Market
Machine learning algorithms go above and beyond when used for cybersecurity as they help in identifying patterns and analyzing huge volumes of data to provide better security suggestions. Preventive threat protection actions can be used by deploying predictive threat detection using machine learning, thereby favoring artificial intelligence (AI) in cybersecurity market growth too. Machine learning is becoming an integral part of all AI-based cybersecurity solutions and systems.
Text-based attacks have increased in prevalence and frequency around the world and this is why the need for natural language processing (NLP) technology is rising rapidly. Use of NLP in AI-based cybersecurity solutions Better communication and a simplified nature of AI-based security can be achieved by the extensive deployment of NLP technology.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/global-ai-in-cybersecurity-market
Identity and Access Management to Remain the Primary Wall in AI-based Cybersecurity Defense
The use of artificial intelligence in identity and access management is projected to take cybersecurity to a new level. Use of multi-factor authentication and single sign-on features can easily be enabled by using AI in identity and access management functions of cybersecurity. The increasing complexity of the regulatory environment to reduce the incidence of cyberattacks is promoting the demand for AI-based risk and compliance management solutions. In the age of information data is the currency and safeguarding this data is of utmost importance to all organizations. Data loss prevention application is also slated to provide attractive opportunities for artificial intelligence (AI) in cybersecurity companies in the long run.
Artificial intelligence (AI) in cybersecurity market players should take caution while investing in any of the segments of this market as this is a highly sensitive and regulated industry. Targeting the use of machine learning and natural language processing algorithms in this market could be highly rewarding for new as well as established artificial intelligence (AI) in cybersecurity companies in the near future.
Related Report:
AI Market 
Cyber Security Market
Artificial Intelligence (AI) in Computer Vision Market
Edge Artificial Intelligence (AI) Market
Artificial Intelligence (AI) Hardware Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact:Mr. Jagraj SinghSkyQuest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-ai-in-cybersecurity-market-to-surpass-usd-114-30-billion-valuation-in-2031-on-the-back-of-rapidly-evolving-threat-landscape–skyquest-technology-302195619.html

Continue Reading
Advertisement
Stake.com
Advertisement

Latest News

Trending